Home » Stocks » REPH

Recro Pharma, Inc. (REPH)

Stock Price: $1.89 USD -0.03 (-1.56%)
Updated Jul 26, 2021 10:11 AM EDT - Market open
Market Cap 89.01M
Revenue (ttm) 61.53M
Net Income (ttm) -26.57M
Shares Out 46.36M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE 18.25
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $1.89
Previous Close $1.92
Change ($) -0.03
Change (%) -1.56%
Day's Open 1.92
Day's Range 1.88 - 1.99
Day's Volume 74,913
52-Week Range 1.49 - 5.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and ...

1 week ago - GlobeNewsWire

Recro Pharma (REPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 weeks ago - Zacks Investment Research

Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Su...

1 month ago - GlobeNewsWire

Addition of Clinical-Scale Sachet and Blister Packaging Services Further Broadens CTS Offerings; Successful Audit of Facility by EU Qualified Person (QP) Represents Key Step for Attracting and Onboardin...

1 month ago - GlobeNewsWire

Underwriters' Full Exercise of Option Brings Gross Proceeds to $34.5 Million

2 months ago - GlobeNewsWire

EXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufactur...

2 months ago - GlobeNewsWire

EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufactur...

2 months ago - GlobeNewsWire

Revenues of $16.8 Million Represent an Increase of 70% Compared to Q4 2020 Revenue

2 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for Thursday, May 6 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Thursday, May 6 at 4:30 p.m. Eastern Time

2 months ago - GlobeNewsWire

Additional Contract Broadens and Further Strengthens Customer Product Portfolio Additional Contract Broadens and Further Strengthens Customer Product Portfolio

3 months ago - GlobeNewsWire

MALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manuf...

3 months ago - GlobeNewsWire

Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing

3 months ago - GlobeNewsWire

Strengthened Industry-Centric Leadership

5 months ago - GlobeNewsWire

Conference Call and Webcast Moved Up to 8:00 a.m. Eastern on Friday, February 26 Conference Call and Webcast Moved Up to 8:00 a.m. Eastern on Friday, February 26

5 months ago - GlobeNewsWire

Reductions in Debt Principal and Interest Rate Further Strengthen Balance Sheet, Support Ongoing Efforts to Best Position Company for Significant CDMO Business Growth Reductions in Debt Principal and In...

5 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for Friday, February 26 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Friday, February 26 at 4:30 p.m. Eastern Time

5 months ago - GlobeNewsWire

MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services,...

7 months ago - GlobeNewsWire

Perhaps this year like no other has demonstrated the yin-yang effect of the market. While we've seen incredible winners, these companies represent the worst performing stocks of 2020.

Other stocks mentioned: AHT, FARM, GLBS, ICD, JE, MITT
7 months ago - InvestorPlace

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

  Shares of Recro Pharma (NASDAQ:REPH) were unchanged after the company reported Q3 results.

8 months ago - Benzinga

Company Secures Three-Year Renewal of Licens e and Supply Agreement with Lannett , A Generic s Pharmaceutical Company, for Manufacturing of Verelan PM ® , Verelan SR ® and Verapamil PM

8 months ago - GlobeNewsWire

GAINESVILLE, Ga., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulati...

10 months ago - GlobeNewsWire

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Shares of Recro Pharma (NASDAQ:REPH) were flat in pre-market trading after the company reported Q2 results.

11 months ago - Benzinga

Launches Clinical Trial Materials Business and Secures New Customers

11 months ago - GlobeNewsWire

Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second quarter. ...

Other stocks mentioned: CNCE, CRDF, IDN, VRTV
1 year ago - Forbes

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Other stocks mentioned: BKYI, COCP, EYES, EYPT
1 year ago - Forbes

Company Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products

1 year ago - GlobeNewsWire

Recro Pharma (REPH) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Recro Pharma, Inc.'s (REPH) CEO Gerri Henwood on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Recro Capitalizing on Strong and Growing CDMO Business

1 year ago - GlobeNewsWire

Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets

1 year ago - GlobeNewsWire

Separation of Baudax Bio as Independent Company Expected to be Completed  With Distribution on November 21, 2019

1 year ago - GlobeNewsWire

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Recro Pharma (REPH) delivered earnings and revenue surprises of -46.15% and 27.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Recro Pharma: FDA Grants Appeal For IV Meloxicam, Adding Value To The Proposed Acute Care Spin-Out

1 year ago - Seeking Alpha

Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request

1 year ago - GlobeNewsWire

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Excluding the IV meloxicam CRL, Recro Pharma has a strong 2019 with cutting OpEx and moving closer to cash flow positive. However, management is looking to spin-out the acute care segment.

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor Recro Pharma.

1 year ago - Zacks Investment Research

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Recro Pharma (REPH) delivered earnings and revenue surprises of 63.89% and 29.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.

Other stocks mentioned: AFMD, ARWR, INCY, RGEN, VCYT, VRTX
2 years ago - InvestorPlace

These stocks to buy are low-priced, top quality choices for growth. Here's what you need to know about each.

Other stocks mentioned: DHT, FSI, IGC, SACH
2 years ago - InvestorPlace

Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Recro Pharma (REPH) delivered earnings and revenue surprises of 87.34% and 22.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

Recro Pharma (REPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About REPH

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Mar 7, 2014
Stock Exchange
NASDAQ
Ticker Symbol
REPH
Full Company Profile

Financial Performance

In 2020, Recro Pharma's revenue was $66.50 million, a decrease of -32.98% compared to the previous year's $99.22 million. Losses were -$27.50 million, 47.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Recro Pharma stock is "Strong Buy." The 12-month stock price forecast is 5.50, which is an increase of 191.01% from the latest price.

Price Target
$5.50
(191.01% upside)
Analyst Consensus: Strong Buy